&lt;p&gt;Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma&lt;/p&gt;

Wang, Haiying; Chu, Junfeng; Zhang, Peng; Wang, Jiaqiang; Zheng, Yan; Yao, Shuna; Yao, Zhihua; Liu, Yanyan

doi:10.2147/ott.s235349

Cited by 41 publications

(43 citation statements)

References 35 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In so-doing, it effectively suppresses tumor angiogenesis and growth, with acceptable toxicity as seen in lu ng squamous cell carcinoma, advanced lung adenocarcinoma, small cell lung cancer, soft tissue sarcoma, medullary thyroid cancer, and metastatic renal clear cell cancer (Han et al, 2018;Sun et al, 2018;Shao et al, 2019;Yang et al, 2019;Zhou et al, 2019). Its major side effects include fatigue, high blood pressure, hand-foot skin reaction, gastrointestinal reactions, triglyceride elevation cholesterol elevation, and blood thyrotrophin elevation (Sun et al, 2016;Shao et al, 2019;Wang et al, 2020). To rule out other factors contributing this patient's hypertensive retinopathy, such as possible drug interactions, diet, and congenital factors, a detailed medical history was performed.…”

Section: Discussionmentioning

confidence: 99%

Hypertensive Retinopathy Secondary to Anlotinib Treatment

Zhang

Xie

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Purpose: We report a case of a middle-aged woman who developed hypertensive retinopathy following oral administration of Anlotinib. Observations: A 48-year-old woman presented to our hospital with sudden painless loss of vision in both eyes combined with headache, nausea, and vomiting following oral administration of Anlotinib. This drug is often used to control cancer progression. Due to the deterioration of her blood pressure, which reached 167/113 mm Hg, Anlotinib was discontinued and the blood pressure was controlled by hypertension medications. This normalized her blood pressure, alleviated headache, and restored her vision. She visited our eye department 37 days later for eye checkup. The best-corrected visual acuities was 0.3 in the right eye and 0.4 in the left eye. The fundus examinations revealed a clear boundary of the optic papilla with significant stellate exudation in the macular area. The posterior pole of the retina displayed high hemorrhage, with a cotton-wool spot appearance. Optical coherence tomography (OCT) revealed atrophy in the outer segment of macular area, and hard exudations in retinal layers. Based on these findings, hypertensive retinopathy was diagnosed, as a secondary complication of Anlotinib. Conclusions and Significance: Anlotinib can induce hypertensive retinopathy. Patients receiving this drug should be closely monitored for potential complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Hypertensive Retinopathy Secondary to Anlotinib Treatment

Zhang

Xie

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In a retrospective study, chemotherapy combined with anlotinib plus anlotinib maintenance therapy showed good efficacy and resulted in more favorable survival with good tolerance in advanced soft tissue sarcoma[ 18 ]. For the first time, we report the effects of NAC combined with anlotinib in the treatment of OBC.…”

Section: Discussionmentioning

confidence: 99%

Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature

Wu¹,

Zhao²,

Tian³

et al. 2021

WJCC

View full text Add to dashboard Cite

BACKGROUND Occult breast cancer (OBC) is a special type of breast cancer presenting as axillary lymph node metastasis with undetectable primary lesions in the breast. Due to its low incidence and unique clinical manifestations, there is a lack of consensus on the diagnosis and treatment of OBC. We report a case of OBC treated with neoadjuvant chemotherapy combined with anlotinib. The treatment was well tolerated, and the patient achieved a pathologic complete response. CASE SUMMARY A 53-year-old woman presented with a lump in her right axillary area with no primary lesions in the breast. Pathological biopsy confirmed right axillary metastatic carcinoma. Immunohistochemical staining results were positive for progesterone receptor, cytokeratin 7, specific breast markers GATA3 and gross cystic disease fluid protein-15. Tumor cells were negative for estrogen receptor, human epidermal growth factor receptor-2, cytokeratin 5/6, cytokeratin 20, and villin. The patient was diagnosed with OBC, and she underwent neoadjuvant chemotherapy combined with anlotinib. Mastectomy plus axillary lymph node dissection was performed. The patient achieved pathologic complete response with no residual invasive tumor cells in the breast or axillary lymph nodes. Postoperatively, she received adjuvant radiotherapy and endocrine therapy. CONCLUSION Neoadjuvant chemotherapy and anlotinib had good efficacy and safety in the treatment of OBC and may be a new therapeutic option.

show abstract

“…Anlotinib also has encouraging antitumor effects and acceptable toxicity in advanced NSCLC, small cell lung carcinoma, medullary thyroid cancer, soft tissue sarcomas and metastatic renal clear cell cancer. [24][25][26][27][28] A multicenter, double-blind, Phase III randomized clinical trial (ALTER 0303) of patients with advanced NSCLC who progressed after second-line or later treatment showed that compared with the placebo group, the anlotinib group had a significantly longer PFS (5.4 vs 1.4 months; P < 0.001) and OS (9.6 vs 6.3 months; P < 0.001) and a higher ORR (9.2% vs 0.7%; P < 0.001) and DCR (81.0% vs 37.1%; P < 0.001). 18 As a novel multitargeted kinase inhibitor, anlotinib, which inhibits not only tumor cell proliferation but also tumor angiogenesis, is the first drug approved in China as third-line therapy for metastatic/advanced NSCLC.…”

Section: Discussionmentioning

confidence: 99%

<p>A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer</p>

Wang

Chu

Zhao

et al. 2020

CMAR

Self Cite

View full text Add to dashboard Cite

Purpose: Anlotinib is a newly developed oral multitarget tyrosine kinase inhibitor. We retrospectively evaluated the toxicity and clinical efficacy of chemotherapy combined with anlotinib versus chemotherapy alone for metastatic/advanced non-small cell lung cancer (NSCLC) in patients who failed firstor second-line systemic treatment in China. Patients and Methods: In this retrospective trial, ninety-four advanced NSCLC patients received chemotherapy combined with anlotinib (n = 41) or chemotherapy alone (n = 53) in Henan Cancer Hospital. We recorded the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and adverse events (AEs). Results: In the anlotinib plus chemotherapy group, eleven patients (27%) achieved a PR (partial response), and twenty-one patients (51%) achieved SD (stable disease), with an ORR of 27% and a DCR of 78%. In the chemotherapy alone group, eight patients (15%) achieved a PR, and nineteen patients (36%) had SD, with an ORR of 15% and a DCR of 51%. The ORR in the combination arm was slightly, but not obviously, higher than that in the chemotherapy arm (27% vs 15%, p > 0.05). In addition, the DCR was significantly higher in the combination arm than in the chemotherapy alone arm (78% vs 51%, p=0.007). At the end of follow-up, patients in the combination arm had a 1.5-month longer median PFS than patients in the chemotherapy arm; this difference was statistically significant (5.0 vs 3.5, p=0.002). The median OS was not achieved at the final analysis. The hematological and nonhematological toxicities were well tolerated and controlled. In general, most toxicity was limited to grade I or II, well tolerated and controlled. Conclusion: Our study suggests that anlotinib combined with chemotherapy may be an effective and well-tolerated treatment for advanced NSCLC in patients who fail firstor second-line therapy.

show abstract

<p>Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma</p>

Cited by 41 publications

References 35 publications

Hypertensive Retinopathy Secondary to Anlotinib Treatment

Hypertensive Retinopathy Secondary to Anlotinib Treatment

Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature

<p>A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer</p>

Contact Info

Product

Resources

About